Company news

Share this article:
Lilly will pay $62 million to 32 states investigating the company over its marketing of Zyprexa, an antipsychotic drug indicated for schizophrenia and some forms of bipolar disorder. Eleven other states – and the federal government – will continue to investigate Zyprexa promotions, and may cost the company more money in the future. The company is accused of marketing the drug off-label, for dementia and milder forms of bipolar disorder that have not been approved by FDA.

AtheroGenics, an Alpharetta, GA–based pharmaceutical company, filed for Chapter 11 bankruptcy on September 15 in the US Bankruptcy Court for the Northern District of Georgia in Atlanta, due to a substantial debt burden. AtheroGenics expects to sell the company and/or its key assets. AtheroGenics focused on the treatment of chronic inflammatory diseases including diabetes and coronary heart disease.   
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.